APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae

Compare research editions
View pricing & licenses

Selected research

Industry Research

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Research Report 2026

23 December 2025142 pages

Choose your research edition.

Industry ResearchDrugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae include Takeda Pharmaceutical, CSPC, Shenzhen Lijian Pharmaceutical, Sanofi, Merck & Co., Inc. (USA), Roche, Pfizer Inc. (USA), NCPC and Sinopharm Group, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Company

Takeda Pharmaceutical

CSPC

Shenzhen Lijian Pharmaceutical

Sanofi

Merck & Co., Inc. (USA)

Roche

Pfizer Inc. (USA)

NCPC

Sinopharm Group

GlaxoSmithKline plc (UK)

Daiichi Sankyo

Bayer

AbbVie

Sun Pharmaceutical

Lupin

Hikma Pharmaceuticals

Dr. Reddy's Laboratories

Cipla

Celltrion

Astellas Pharma Inc. (Japan)

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Type

Ceftriaxone

Doxycycline

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Application

Retail Pharmacy

Hospital

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2021-2026) Table 7. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Type (2027-2032) Table 9. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2021-2026) Table 11. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Application (2027-2032) Table 13. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region (2021-2026) Table 16. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region (2027-2032) Table 18. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends Table 19. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Drivers Table 20. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Opportunities and Challenges Table 21. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Restraints Table 22. Global Top Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Players (2021-2026) Table 24. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae, Headquarters and Area Served Table 26. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032) & (US$ Million) Table 45. Takeda Pharmaceutical Company Information Table 46. Takeda Pharmaceutical Business Overview Table 47. Takeda Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 48. Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 49. Takeda Pharmaceutical Recent Developments Table 50. CSPC Company Information Table 51. CSPC Business Overview Table 52. CSPC Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 53. CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 54. CSPC Recent Developments Table 55. Shenzhen Lijian Pharmaceutical Company Information Table 56. Shenzhen Lijian Pharmaceutical Business Overview Table 57. Shenzhen Lijian Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 58. Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 59. Shenzhen Lijian Pharmaceutical Recent Developments Table 60. Sanofi Company Information Table 61. Sanofi Business Overview Table 62. Sanofi Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 63. Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 64. Sanofi Recent Developments Table 65. Merck & Co., Inc. (USA) Company Information Table 66. Merck & Co., Inc. (USA) Business Overview Table 67. Merck & Co., Inc. (USA) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 68. Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 69. Merck & Co., Inc. (USA) Recent Developments Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 73. Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 74. Roche Recent Developments Table 75. Pfizer Inc. (USA) Company Information Table 76. Pfizer Inc. (USA) Business Overview Table 77. Pfizer Inc. (USA) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 78. Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 79. Pfizer Inc. (USA) Recent Developments Table 80. NCPC Company Information Table 81. NCPC Business Overview Table 82. NCPC Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 83. NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 84. NCPC Recent Developments Table 85. Sinopharm Group Company Information Table 86. Sinopharm Group Business Overview Table 87. Sinopharm Group Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 88. Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 89. Sinopharm Group Recent Developments Table 90. GlaxoSmithKline plc (UK) Company Information Table 91. GlaxoSmithKline plc (UK) Business Overview Table 92. GlaxoSmithKline plc (UK) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 93. GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 94. GlaxoSmithKline plc (UK) Recent Developments Table 95. Daiichi Sankyo Company Information Table 96. Daiichi Sankyo Business Overview Table 97. Daiichi Sankyo Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 98. Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 99. Daiichi Sankyo Recent Developments Table 100. Bayer Company Information Table 101. Bayer Business Overview Table 102. Bayer Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 103. Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 104. Bayer Recent Developments Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 108. AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 109. AbbVie Recent Developments Table 110. Sun Pharmaceutical Company Information Table 111. Sun Pharmaceutical Business Overview Table 112. Sun Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 113. Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 114. Sun Pharmaceutical Recent Developments Table 115. Lupin Company Information Table 116. Lupin Business Overview Table 117. Lupin Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 118. Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 119. Lupin Recent Developments Table 120. Hikma Pharmaceuticals Company Information Table 121. Hikma Pharmaceuticals Business Overview Table 122. Hikma Pharmaceuticals Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 123. Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 124. Hikma Pharmaceuticals Recent Developments Table 125. Dr. Reddy's Laboratories Company Information Table 126. Dr. Reddy's Laboratories Business Overview Table 127. Dr. Reddy's Laboratories Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 128. Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 129. Dr. Reddy's Laboratories Recent Developments Table 130. Cipla Company Information Table 131. Cipla Business Overview Table 132. Cipla Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 133. Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 134. Cipla Recent Developments Table 135. Celltrion Company Information Table 136. Celltrion Business Overview Table 137. Celltrion Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 138. Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 139. Celltrion Recent Developments Table 140. Astellas Pharma Inc. (Japan) Company Information Table 141. Astellas Pharma Inc. (Japan) Business Overview Table 142. Astellas Pharma Inc. (Japan) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) & (US$ Million) Table 143. Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 144. Astellas Pharma Inc. (Japan) Recent Developments Table 145. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Image Figure 5. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Type: 2025 VS 2032 Figure 7. Ceftriaxone Product Figure 8. Doxycycline Product Figure 9. Other Product Figure 10. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Application: 2025 VS 2032 Figure 12. Retail Pharmacy Product Figure 13. Hospital Product Figure 14. Other Product Figure 15. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Region: 2025 VS 2032 Figure 18. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Players in 2025 Figure 19. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Manufacturers Established Date Figure 20. Global Top 5 and 10 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 24. United States Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 27. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 29. Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 39. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 44. Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Share by Country (2021-2032) Figure 49. Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Takeda Pharmaceutical Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 55. CSPC Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 56. Shenzhen Lijian Pharmaceutical Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 57. Sanofi Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 58. Merck & Co., Inc. (USA) Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 59. Roche Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 60. Pfizer Inc. (USA) Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 61. NCPC Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 62. Sinopharm Group Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 63. GlaxoSmithKline plc (UK) Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 64. Daiichi Sankyo Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 65. Bayer Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 66. AbbVie Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 67. Sun Pharmaceutical Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 68. Lupin Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 69. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 70. Dr. Reddy's Laboratories Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 71. Cipla Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 72. Celltrion Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026) Figure 73. Astellas Pharma Inc. (Japan) Revenue Growth Rate in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)

Scope & coverage.

Types
  • Ceftriaxone
  • Doxycycline
  • Other
Applications
  • Retail Pharmacy
  • Hospital
  • Other
Companies covered
  • Takeda Pharmaceutical
  • CSPC
  • Shenzhen Lijian Pharmaceutical
  • Sanofi
  • Merck & Co., Inc. (USA)
  • Roche
  • Pfizer Inc. (USA)
  • NCPC
  • Sinopharm Group
  • GlaxoSmithKline plc (UK)
  • Daiichi Sankyo
  • Bayer
  • AbbVie
  • Sun Pharmaceutical
  • Lupin
  • Hikma Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Cipla
  • Celltrion
  • Astellas Pharma Inc. (Japan)

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Ceftriaxone
  5. 2.2.3 Doxycycline
  6. 2.2.4 Other
  7. 2.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 Retail Pharmacy
  10. 2.3.3 Hospital
  11. 2.3.4 Other
  12. 2.4 Assumptions and Limitations
3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Breakdown Data by Type
  1. 3.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Historic Market Size by Type (2021-2026)
  2. 3.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Type (2027-2032)
4 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Breakdown Data by Application
  1. 4.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Historic Market Size by Application (2021-2026)
  2. 4.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Perspective (2021-2032)
  2. 5.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Growth Trends by Region
  3. 5.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Historic Market Size by Region (2021-2026)
  5. 5.2.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Forecasted Market Size by Region (2027-2032)
  6. 5.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Dynamics
  7. 5.3.1 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends
  8. 5.3.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Drivers
  9. 5.3.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Challenges
  10. 5.3.4 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players by Revenue
  2. 6.1.1 Global Top Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players by Revenue (2021-2026)
  3. 6.1.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Head Office and Area Served
  6. 6.4 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Players, Product Type & Application
  7. 6.5 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Manufacturers Established Date
  8. 6.6 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  2. 7.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026)
  4. 7.4 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  2. 8.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026)
  4. 8.4 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  2. 9.2 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  2. 10.2 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026)
  4. 10.4 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  2. 11.2 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Takeda Pharmaceutical
  2. 12.1.1 Takeda Pharmaceutical Company Information
  3. 12.1.2 Takeda Pharmaceutical Business Overview
  4. 12.1.3 Takeda Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  5. 12.1.4 Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  6. 12.1.5 Takeda Pharmaceutical Recent Developments
  7. 12.2 CSPC
  8. 12.2.1 CSPC Company Information
  9. 12.2.2 CSPC Business Overview
  10. 12.2.3 CSPC Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  11. 12.2.4 CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  12. 12.2.5 CSPC Recent Developments
  13. 12.3 Shenzhen Lijian Pharmaceutical
  14. 12.3.1 Shenzhen Lijian Pharmaceutical Company Information
  15. 12.3.2 Shenzhen Lijian Pharmaceutical Business Overview
  16. 12.3.3 Shenzhen Lijian Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  17. 12.3.4 Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  18. 12.3.5 Shenzhen Lijian Pharmaceutical Recent Developments
  19. 12.4 Sanofi
  20. 12.4.1 Sanofi Company Information
  21. 12.4.2 Sanofi Business Overview
  22. 12.4.3 Sanofi Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  23. 12.4.4 Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  24. 12.4.5 Sanofi Recent Developments
  25. 12.5 Merck & Co., Inc. (USA)
  26. 12.5.1 Merck & Co., Inc. (USA) Company Information
  27. 12.5.2 Merck & Co., Inc. (USA) Business Overview
  28. 12.5.3 Merck & Co., Inc. (USA) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  29. 12.5.4 Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  30. 12.5.5 Merck & Co., Inc. (USA) Recent Developments
  31. 12.6 Roche
  32. 12.6.1 Roche Company Information
  33. 12.6.2 Roche Business Overview
  34. 12.6.3 Roche Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  35. 12.6.4 Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  36. 12.6.5 Roche Recent Developments
  37. 12.7 Pfizer Inc. (USA)
  38. 12.7.1 Pfizer Inc. (USA) Company Information
  39. 12.7.2 Pfizer Inc. (USA) Business Overview
  40. 12.7.3 Pfizer Inc. (USA) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  41. 12.7.4 Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  42. 12.7.5 Pfizer Inc. (USA) Recent Developments
  43. 12.8 NCPC
  44. 12.8.1 NCPC Company Information
  45. 12.8.2 NCPC Business Overview
  46. 12.8.3 NCPC Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  47. 12.8.4 NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  48. 12.8.5 NCPC Recent Developments
  49. 12.9 Sinopharm Group
  50. 12.9.1 Sinopharm Group Company Information
  51. 12.9.2 Sinopharm Group Business Overview
  52. 12.9.3 Sinopharm Group Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  53. 12.9.4 Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  54. 12.9.5 Sinopharm Group Recent Developments
  55. 12.10 GlaxoSmithKline plc (UK)
  56. 12.10.1 GlaxoSmithKline plc (UK) Company Information
  57. 12.10.2 GlaxoSmithKline plc (UK) Business Overview
  58. 12.10.3 GlaxoSmithKline plc (UK) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  59. 12.10.4 GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  60. 12.10.5 GlaxoSmithKline plc (UK) Recent Developments
  61. 12.11 Daiichi Sankyo
  62. 12.11.1 Daiichi Sankyo Company Information
  63. 12.11.2 Daiichi Sankyo Business Overview
  64. 12.11.3 Daiichi Sankyo Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  65. 12.11.4 Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  66. 12.11.5 Daiichi Sankyo Recent Developments
  67. 12.12 Bayer
  68. 12.12.1 Bayer Company Information
  69. 12.12.2 Bayer Business Overview
  70. 12.12.3 Bayer Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  71. 12.12.4 Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  72. 12.12.5 Bayer Recent Developments
  73. 12.13 AbbVie
  74. 12.13.1 AbbVie Company Information
  75. 12.13.2 AbbVie Business Overview
  76. 12.13.3 AbbVie Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  77. 12.13.4 AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  78. 12.13.5 AbbVie Recent Developments
  79. 12.14 Sun Pharmaceutical
  80. 12.14.1 Sun Pharmaceutical Company Information
  81. 12.14.2 Sun Pharmaceutical Business Overview
  82. 12.14.3 Sun Pharmaceutical Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  83. 12.14.4 Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  84. 12.14.5 Sun Pharmaceutical Recent Developments
  85. 12.15 Lupin
  86. 12.15.1 Lupin Company Information
  87. 12.15.2 Lupin Business Overview
  88. 12.15.3 Lupin Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  89. 12.15.4 Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  90. 12.15.5 Lupin Recent Developments
  91. 12.16 Hikma Pharmaceuticals
  92. 12.16.1 Hikma Pharmaceuticals Company Information
  93. 12.16.2 Hikma Pharmaceuticals Business Overview
  94. 12.16.3 Hikma Pharmaceuticals Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  95. 12.16.4 Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  96. 12.16.5 Hikma Pharmaceuticals Recent Developments
  97. 12.17 Dr. Reddy's Laboratories
  98. 12.17.1 Dr. Reddy's Laboratories Company Information
  99. 12.17.2 Dr. Reddy's Laboratories Business Overview
  100. 12.17.3 Dr. Reddy's Laboratories Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  101. 12.17.4 Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  102. 12.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 12.18 Cipla
  104. 12.18.1 Cipla Company Information
  105. 12.18.2 Cipla Business Overview
  106. 12.18.3 Cipla Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  107. 12.18.4 Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  108. 12.18.5 Cipla Recent Developments
  109. 12.19 Celltrion
  110. 12.19.1 Celltrion Company Information
  111. 12.19.2 Celltrion Business Overview
  112. 12.19.3 Celltrion Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  113. 12.19.4 Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  114. 12.19.5 Celltrion Recent Developments
  115. 12.20 Astellas Pharma Inc. (Japan)
  116. 12.20.1 Astellas Pharma Inc. (Japan) Company Information
  117. 12.20.2 Astellas Pharma Inc. (Japan) Business Overview
  118. 12.20.3 Astellas Pharma Inc. (Japan) Revenue in Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Business (2021-2026)
  119. 12.20.4 Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  120. 12.20.5 Astellas Pharma Inc. (Japan) Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst